ClinicalTrials.gg
CompletedNCT05488678Updated Dec 8, 2025

Ceftibuten/VNRX-7145 in Participants With Varying Degrees of Renal Function

A Phase 1 interventional study of VNRX-7145 and Ceftibuten in Pharmacokinetics, sponsored by Basilea Pharmaceutica. Completed at 3 sites in United States. Open to participants aged 18 Years to 82 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Basilea Pharmaceutica · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2023, 2 years 11 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 82 Years
Sex
All
01

Study summary

This is an open-label, multicenter, parallel-group study in participants with normal renal function, mild, moderate, or severe renal impairment, or end stage renal disease (ESRD) undergoing standard intermittent dialysis. The pharmacokinetics (PK) of the inactive prodrug VNRX-7145, its active parent drug VNRX-5236, and ceftibuten will be evaluated after a single oral dose of ceftibuten/VNRX-7145.

02

Conditions studied

  • Pharmacokinetics
03

In context

Lead sponsor

Basilea Pharmaceutica is the lead sponsor of 60 studies on the registry; 7 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 15 (68%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 82 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults 18-82 years
  • Males or non-pregnant, non-lactating females
  • (BMI): ≥18.5 kg/m2 and ≤40.0 kg/m2
  • Laboratory values meeting defined entry criteria

Subjects with normal renal function (Group 1) must also meet the following criteria:

  • Match to one or more participants with renal impairment by gender, age, and BMI

Subjects with renal impairment (Groups 2-5) must also meet the following criteria:

  • Stable, pre-existing renal impairment

Exclusion criteria

Exclusion Criteria:

  • History of drug allergy or to penicillin, cephalosporin, or beta-lactam antibacterial drug
  • Congenital or acquired immunodeficiency syndrome
  • Major adverse cardiovascular event within one year of dosing
  • Positive alcohol, drug, or tobacco use/test
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Group 1 - Control

    Healthy control participants will be matched by gender, age, and BMI to participants with renal impairment

    Drug: VNRX-7145 · Drug: Ceftibuten

  • Experimental
    Group 2 - Mild Renal Impairment

    Mild Renal Impairment

    Drug: VNRX-7145 · Drug: Ceftibuten

  • Experimental
    Group 3 - Moderate Renal Impairment

    Moderate Renal Impairment

    Drug: VNRX-7145 · Drug: Ceftibuten

  • Experimental
    Group 4 - Severe Renal Impairment

    Severe Renal Impairment

    Drug: VNRX-7145 · Drug: Ceftibuten

  • Experimental
    Group 5 - End Stage Renal Disease

    End Stage Renal Disease undergoing chronic intermittent hemodialysis

    Drug: VNRX-7145 · Drug: Ceftibuten

Interventions

06

What researchers measure

Primary outcomes

  1. Cmax

    Maximum plasma concentration, determined directly from individual concentration time data

    Time frame: 0-120 hours post dose

  2. AUC0-inf

    Area under the plasma concentration time curve from time zero extrapolated to infinity based on collected PK

    Time frame: 0-120 hours post dose

  3. Number of subjects with adverse events

    Time frame: 8 days post dose

07

Study locations

3 sites
  • Advanced Pharma
    Miami, Florida 33147, United States
  • Orlando Clinical Research Center
    Orlando, Florida 32809, United States
  • Nucleus Network
    Saint Paul, Minnesota 55114, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in Nov 2023, 13 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 4, 2022
StartActual
Oct 12, 2022
Primary completionActual
Nov 23, 2023
CompletionActual
Nov 23, 2023
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05488678
Responsible party
Sponsor
First posted
Aug 4, 2022
Start date
Oct 12, 2022
Primary completion
Nov 23, 2023
Completion
Nov 23, 2023
Last update
Dec 8, 2025

Study contacts

Kamal Hamed, MD
study director · Basilea Pharmaceutica International Ltd, Allschwil

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ledaborbactam etzadroxil

Start the discussion